Last reviewed · How we verify

Leuprorelin Acetate Microspheres for Injection — Competitive Intelligence Brief

Leuprorelin Acetate Microspheres for Injection (Leuprorelin Acetate Microspheres for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology; Endocrinology.

phase 3 GnRH agonist GnRH receptor Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Leuprorelin Acetate Microspheres for Injection (Leuprorelin Acetate Microspheres for Injection) — Changchun GeneScience Pharmaceutical Co., Ltd.. Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Leuprorelin Acetate Microspheres for Injection TARGET Leuprorelin Acetate Microspheres for Injection Changchun GeneScience Pharmaceutical Co., Ltd. phase 3 GnRH agonist GnRH receptor
Lupron leuprorelin Accord Healthcare S.L.U. marketed Gonadotropin Releasing Hormone Receptor Agonist GnRH receptors 1985-01-01
Micronor norethisterone Johnson & Johnson marketed Progestin GnRH receptors 1962-01-01
Lupron Trigger Lupron Trigger Weill Medical College of Cornell University marketed GnRH agonist GnRH receptor
Leuprolide acetate in depot suspension Leuprolide acetate in depot suspension Colorado Center for Reproductive Medicine marketed GnRH agonist GnRH receptor
Leuprolide Depot Leuprolide Depot Enteris BioPharma Inc. marketed GnRH agonist GnRH receptor
GnRH antagonist-Cetrorelix GnRH antagonist-Cetrorelix University of Edinburgh marketed GnRH antagonist GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (GnRH agonist class)

  1. Takeda · 4 drugs in this class
  2. Abbott · 3 drugs in this class
  3. Ipsen · 3 drugs in this class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
  5. University of Pisa · 2 drugs in this class
  6. Chong Qing Reproducive and Genetic Institute · 1 drug in this class
  7. Chesapeake Urology Research Associates · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Enteris BioPharma Inc. · 1 drug in this class
  10. Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leuprorelin Acetate Microspheres for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprorelin-acetate-microspheres-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: